Trial Profile

Phase 1/2, Multicentre, Open-label, Multiple-cohort Study of Dato-DXd in Chinese Patients With Advanced Non-small-cell Lung Cancer, Triple-negative Breast Cancer, Gastric/Gastroesophageal Junction Cancer, Urothelial Cancer, and Other Solid Tumours

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 20 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Datopotamab deruxtecan (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Triple negative breast cancer; Urogenital cancer
Focus Therapeutic Use
Acronyms TROPION-PanTumor02
Sponsors AstraZeneca

13 Jun 2025 Planned End Date changed from 30 Dec 2024 to 31 Dec 2025.
23 Sep 2024 Planned End Date changed from 6 May 2024 to 30 Dec 2024.
04 Jun 2024 Results from the NSCLC cohort presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com